Reading the tape
NASDAQ: DCTH
Delcath Systems, Inc.
Healthcare · Medical - Devices
Market Cap
$382.90M
52w High
$18.23
52w Low
$8.12
P/E
148.75
Volume
358.31K
Outstanding Shares
34.75M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -8.09%Revenue (TTM): 129.08%FCF (TTM): 208.99%P/S: 23rd pct
What changed
The stock fell 8.09% over the last year. Revenue grew 129.08% over the trailing twelve months. Operating margin moved from -33.36% to 0.77%. Free cash flow grew 208.99% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 0.77%. A decisive move in revenue — currently up 129.08% — would be the clearest signal to resolve the ambiguity.
Company profile
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
CEOGerard J. Michel
SectorHealthcare
IndustryMedical - Devices
Employees96
IPO dateMay 3, 2018
Valuation
Forward P/E—
EV/EBITDA82.74
Enterprise value$319.28M
Stock splits
Dec 24, 2019↓ Reverse
Every 700 shares became 1
Oct 22, 2019↓ Reverse
Every 100 shares became 1
May 2, 2018↓ Reverse
Every 500 shares became 1
Nov 6, 2017↓ Reverse
Every 350 shares became 1
Jul 21, 2016↓ Reverse
Every 16 shares became 1
Apr 9, 2014↓ Reverse
Every 16 shares became 1
Profitability & growth
Revenue growth37.27%
Gross margin86.16%▲3.35%vs FY2024
Operating margin0.77%▲102.32%vs FY2024
ROE2.43%▲106.32%vs FY2024
Analyst consensus
RatingBuy
Target price$23.00▲108.71%
8
Buy
2
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.10 · Revenue est $23.51M
View